Unknown

Dataset Information

0

Ridaforolimus.


ABSTRACT: Ridaforolimus (AP23573; MK 8669) is an analog of sirolimus and a small molecule inhibitor of the mammalian target of rapamycin for the treatment of cancer. Both intravenous and oral formulations of the compound are being tested in clinical trials for the treatment of soft-tissue and bone sarcomas. It is in phase III development for sarcoma in the EU and US, and phase II for breast cancer, endometrial cancer, non-small cell lung cancer, and prostate cancer in the US and other markets in the world. This review discusses the key development milestones and therapeutic trials of this drug.

SUBMITTER:  

PROVIDER: S-EPMC3586089 | BioStudies | 2010-01-01

REPOSITORIES: biostudies

Similar Datasets

2012-01-01 | S-EPMC3432676 | BioStudies
2013-01-01 | S-EPMC3716995 | BioStudies
2015-01-01 | S-EPMC5693226 | BioStudies
2016-07-01 | E-GEOD-79492 | ArrayExpress
2014-01-01 | S-EPMC4229637 | BioStudies
2012-01-01 | S-EPMC3313018 | BioStudies
2017-01-01 | S-EPMC5709225 | BioStudies
2013-01-01 | S-EPMC3742690 | BioStudies
2012-01-01 | S-EPMC3542838 | BioStudies
2013-01-01 | S-EPMC3619076 | BioStudies